Changes of bone turnover markers during perioperative anthracycline- and/or taxane-based chemotherapy in pre- and postmenopausal patients with primary breast cancer

被引:0
|
作者
Kurbacher, C. M. [1 ]
Rauschenbach, N. [1 ]
Kurbacher, A. T. [1 ]
Sperling, S. [1 ]
Herz, S. [1 ]
Monreal, K. [1 ]
Kurbacher, J. A. [1 ]
机构
[1] Gynecol Ctr Bonn Friedenspl, Bonn, Nrw, Germany
关键词
D O I
10.1158/1538-7445.SABCS15-P4-10-17
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P4-10-17
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Changes of bone metabolism induced by perioperative anthracycline- and/or taxane-based chemotherapy for primary breast cancer
    Kurbacher, C. M.
    Rauschenbach, N.
    Kurbacher, A. T.
    Herz, S.
    Monreal, K.
    Bartling, C.
    Quade, A.
    Kurbacher, J. A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S325 - S325
  • [2] Influence of anthracycline- and/or taxane-based chemotherapy on bone metabolism of patients with primary breast cancer
    Kurbacher, C. M.
    Rauschenbach, N.
    Kurbacher, A. T.
    Herz, S.
    Monreal, K.
    Bartling, C.
    Kurbacher, J. A.
    Quade, A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [3] Direct effects on bone metabolism induced by perioperative anthracycline- and/or taxane-based chemotherapy depend on the menopausal status of patients with primary breast cancer
    Rauschenbach, Nadine
    Kurbacher, A. Tabea
    Herz, Susanne
    Kurbacher, Jutta A.
    Monreal, Katja
    Sperling, Sandra
    Kurbacher, Christian M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Once weekly epoetin beta in patients with metastatic breast cancer receiving anthracycline- or taxane-based chemotherapy
    Leonard, Robert C.
    Aapro, Matti
    Chen, Stephen
    Dirix, Luc Y.
    Mayordomo, Jose
    Reichert, Dietmar
    Untch, Michael
    ANNALS OF ONCOLOGY, 2004, 15 : 50 - 50
  • [5] Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study
    Mariani, Gabriella
    Galli, Giulia
    Cavalieri, Stefano
    Valagussa, Pinuccia
    Bianchi, Giulia Valeria
    Capri, Giuseppe
    Cresta, Sara
    Ferrari, Laura
    Damian, Silvia
    Duca, Matteo
    de Braud, Filippo
    Moliterni, Angela
    BREAST JOURNAL, 2019, 25 (02): : 237 - 242
  • [6] Efficacy and safety of cyclophosphamide in anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer: a meta-analysis
    Kang, Yi-Kun
    Si, Yi-Ran
    An, Guang-Yu
    Yuan, Peng
    GLAND SURGERY, 2021, 10 (01) : 252 - +
  • [7] Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
    von Minckwitz, Gunter
    Rezai, Mahdi
    Loibl, Sibylle
    Fasching, Peter A.
    Huober, Jens
    Tesch, Hans
    Bauerfeind, Ingo
    Hilfrich, Joern
    Eidtmann, Holger
    Gerber, Bernd
    Hanusch, Claus
    Kuehn, Thorsten
    du Bois, Andreas
    Blohmer, Jens-Uwe
    Thomssen, Christoph
    Costa, Serban Dan
    Jackisch, Christian
    Kaufmann, Manfred
    Mehta, Keyur
    Untch, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2015 - 2023
  • [8] Pathologic Complete Response in Breast Cancer Patients Receiving Anthracycline- and Taxane-Based Neoadjuvant Chemotherapy Evaluating the Effect of Race/Ethnicity
    Chavez-MacGregor, Mariana
    Litton, Jennifer
    Chen, Huiqin
    Giordano, Sharon H.
    Hudis, Clifford A.
    Wolff, Antonio C.
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Bondy, Melissa L.
    Gonzalez-Angulo, Ana Maria
    CANCER, 2010, 116 (17) : 4168 - 4177
  • [9] Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy
    Parker, J. S.
    Prat, A.
    Cheang, M. C. U.
    Lenburg, M. E.
    Paik, S.
    Perou, C. M.
    CANCER RESEARCH, 2009, 69 (24) : 598S - 598S
  • [10] Dose-dense anthracycline- and taxane-based chemotherapy remains the preferred treatment for selected patients with high-risk early breast cancer
    Lambertini, Matteo
    Nordenskjold, Bo
    LANCET REGIONAL HEALTH-EUROPE, 2025, 49